Skip to Main Content

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

Conditions

Diseases of the Musculoskeletal System | Diseases of the Nervous System

Phase II

What is the purpose of this trial?

Brief Summary:

The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.

  • Trial with
    Ra Pharmaceuticals, Inc.
  • Start Date
    04/19/2018
  • End Date
    12/30/2018
Trial Image

For more information about this study, contact:

Bailey Munro Sheldon

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    05/07/2018
  • Study HIC
    #2000021849